Answers are grounded in this paper and cite their sources.
The first quarter of the 21st century has been marked by the recognition of antimicrobial resistance as a critical global health challenge, prompting the scientific community to develop innovative strategies against high-risk multidrug-resistant pathogens. Furthermore, since the 20th century, knowledge has been progressively accumulating, enabling an understanding of the nature of chronic infections. These interconnected issues have driven the exploration of novel antibacterial agents as alternatives to conventional antibiotics. Among these, enzybiotics, based on peptidoglycan-degrading enzymes, are particularly promising. However, the active substance of enzybiotics is a double-edged sword because its structural complexity may be beneficial in combating difficult-to-treat infections, but demands precise stabilization and formulation optimization to ensure the efficacy of a final dosage form. Over the past 10 years, significant progress in research has been observed in the development of topical preparations for the treatment of skin and soft tissue infections. In this review, we have analyzed contemporary research focused on the development of formulations for such enzybiotics, identified key R&D directions and challenges, and discussed the importance of these aspects for establishing a pipeline for new generations of biotechnological antibacterial agents.
No takes yet. Share an insight, caveat, or question.
Lendel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: